Home › Chronic Myeloid Leukemia
Chronic Myeloid Leukemia clinical trials recruiting in the U.S.
49 studies for Chronic Myeloid Leukemia are recruiting participants at sites across the United States.
Chronic myeloid leukemia (CML) is a cancer of the white blood cells. It usually affects older adults. Learn about symptoms, genetics, and treatment.
Cities with the most studies
- Houston, TX18 studies
- Seattle, WA11 studies
- New York City, NY10 studies
- Portland, OR7 studies
- Baldwin Park, CA7 studies
- Chicago, IL7 studies
- Detroit, MI6 studies
- Birmingham, AL6 studies
- Philadelphia, PA6 studies
- St. Louis, MO6 studies
- Milwaukee, WI5 studies
- Nashville, TN5 studies
- Atlanta, GA5 studies
- Boston, MA5 studies
- Columbus, OH5 studies
- Baltimore, MD5 studies
- Durham, NC5 studies
- Cincinnati, OH5 studies
- Salt Lake City, UT4 studies
- Augusta, GA4 studies
- Rochester, NY4 studies
- Kansas City, MO4 studies
- Mountain View, CA4 studies
- Washington, DC4 studies
- Edison, NJ4 studies
- Buffalo, NY3 studies
- St. Petersburg, FL3 studies
- Orange, CA3 studies
- Cleveland, OH3 studies
- Madison, WI3 studies
- Minneapolis, MN3 studies
- Miami, FL3 studies
- Sacramento, CA3 studies
- Greenville, NC3 studies
- Ann Arbor, MI3 studies
- Bridgeport, CT3 studies
- Aurora, CO3 studies
By state
- Alabama6 studies
- Arizona5 studies
- California11 studies
- Colorado4 studies
- District of Columbia3 studies
- Florida7 studies
- Georgia7 studies
- Illinois7 studies
- Indiana3 studies
- Kansas5 studies
- Kentucky3 studies
- Maryland6 studies
- Massachusetts5 studies
- Michigan7 studies
- Minnesota4 studies
- Missouri6 studies
- Nebraska3 studies
- New Jersey4 studies
- New York14 studies
- North Carolina8 studies
- Ohio10 studies
- Oregon7 studies
- Pennsylvania7 studies
- Tennessee5 studies
- Texas18 studies
- Utah4 studies
- Virginia4 studies
- Washington11 studies
- Wisconsin6 studies
Recently updated studies
Allogeneic iNKT Cell Therapy (agenT-797) After SCT
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT07758218Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia
RecruitingPhase 2
Ages 18 to 65 · All sexes · Updated Nov 12, 2026 · NCT02115295Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP
RecruitingPhase 2
Ages 1 to 18 · All sexes · Updated Nov 10, 2026 · NCT07354074Axatilimab With or Without Azacitidine for the Treatment of Patients With Advanced Phase Myeloproliferative Neoplasms, Myeloproliferative Neoplasm/Myelodysplastic Syndrome Overlap or High Risk Chronic Myelomonocytic Leukemia
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Nov 9, 2026 · NCT06523556Asciminib Roll-over Study
RecruitingPhase 4
Ages 7 to 100 · All sexes · Updated Nov 9, 2026 · NCT04877522HPC Offered for PRESERVE Expansion
RecruitingObservational study
Ages 12 to 80 · All sexes · Updated Nov 6, 2026 · NCT07145411Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
RecruitingObservational studyHealthy volunteers welcome
Ages 40 to 75 · All sexes · Updated Nov 4, 2026 · NCT05334069Phase II Study Assessing Efficacy and Safety of Asciminib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase.
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 2, 2026 · NCT06236724Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies
RecruitingPhase 1
Ages 18 to 120 · All sexes · Updated Nov 2, 2026 · NCT06904066Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
RecruitingObservational study
Ages 0 to 38 · All sexes · Updated Oct 29, 2026 · NCT06131801Prophylactic DLI-X for Leukemia Relapse After HCT
RecruitingPhase 1
Up to age 65 · All sexes · Updated Oct 29, 2026 · NCT07254793Cancer Experience Registry (CER) for Cancer Patients and Caregivers
RecruitingObservational studyHealthy volunteers welcome
Ages 18 and older · All sexes · Updated Oct 29, 2026 · NCT02333604Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
RecruitingObservational study
Ages 18 to 120 · All sexes · Updated Oct 28, 2026 · NCT01137643Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases
RecruitingPhase 2
6 Months – 65 Years · All sexes · Updated Oct 26, 2026 · NCT06013423CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant
RecruitingPhase 2Healthy volunteers welcome
Ages 18 to 75 · All sexes · Updated Oct 23, 2026 · NCT06059391Therapeutic RSK1 Targeting in Myeloid Malignancies
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 21, 2026 · NCT07379125TGRX-678 US Phase I for Chronic Myelogenous Leukemia Patients
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Oct 20, 2026 · NCT06088888A Clinical Study of MK-4208/TERN-701 in Participants With Chronic Myeloid Leukemia (CML) (MK-4208-003/Tern701-1012/CARDINAL)
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 15, 2026 · NCT06163430Phase II Study Assessing the Safety and Efficacy of Dasatinib in Combination With Ropeginterferon in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 13, 2026 · NCT07269470Chart Review Study of Chronic Myelogenous Leukemia (CML) Patients Treated With Imatinib Outside of a Clinical Trial
RecruitingObservational study
All ages · All sexes · Updated Oct 7, 2026 · NCT00816114Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Bone Marrow or Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies
RecruitingEarly phase 1
Ages 18 and older · All sexes · Updated Oct 5, 2026 · NCT06398457Phase II Study Assessing the Efficacy and Toxicity of Olverembatinib Monotherapy in Patients With Chronic Myeloid Leukemia in Chronic Phase After Failing One Prior Therapy With a Second Generation Tyrosine Kinase Inhibitor or Asciminib
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Oct 1, 2026 · NCT06817720Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy
RecruitingPhase 1
Ages 1 and older · All sexes · Updated Sep 18, 2026 · NCT03630991Ponatinib Hydrochloride as Second Line Therapy in Treating Patients With Chronic Myeloid Leukemia in Chronic Phase Resistant or Intolerant to Imatinib Mesylate, Dasatinib, or Nilotinib
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 16, 2026 · NCT01746836Study of Olverembatinib (HQP1351) in Patients With CML-CP
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 15, 2026 · NCT06423911From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.